Funding
Seed+ · Biotech

Excalipoint Therapeutics raises $27.7m Seed+ round

MPCi, Centurium Capital, LAV and other backers participated in the T-cell therapy developer's financing.

Updated Oct 16, 2026By RoundOS Funding desk

Excalipoint Therapeutics raised $27.7 million in Seed+ financing on March 18. Participants included MPCi, Centurium Capital, LAV, Eisai Innovation, Apricot Capital and 5Y Capital. The company develops T-cell engager therapies for cancer and autoimmune diseases.

Funding history

Seed+ · This round$27.7M

Sources

  1. Excalipoint Therapeuticsprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related